BARDA FY2016 BAA

Wendell Conyers / George Keane / Sherica Teshome
October 14, 2015

Resilient People. Healthy Communities. A Nation Prepared.
Overview

- Introduction
- Why use a BAA
- Benefits of a BAA
- Eligible Offerors
- Part I – Application Process
- Part II – Evaluation Process
- Questions
Introduction

The Biomedical Advanced Research and Development Authority (BARDA) solicits the advanced research and development of medical countermeasures for chemical, biological, radiological, and nuclear agents that threaten the U.S. civilian population. BARDA anticipates that research and development activities awarded under this BAA will serve to advance candidate medical countermeasures towards licensure or approval by the Food and Drug Administration (FDA).

Under a BAA, both procurement contracts and non-procurement instruments including Interagency Agreements (IAAs), Grants, Cooperative Agreements, and Other Transaction Agreements (OTAs) may be awarded.
Why use a BAA?

Streamlines the procurement process:

- Multiple submission periods possible
- Amend the BAA to add or subtract information or requirements
- Remain open for extended time
- Current solicitations open for two years

**Expedite** the Identification, Development, and Manufacturing of Medical Countermeasures against Infectious Diseases
BAA Benefits

- Opportunity to gain responses for research areas of interest
- The government may benefit from the ingenuity of our industry/academic partners
- Offerors can provide proposal’s with unique solutions
Eligible Offerors

- Who is eligible for award?

- Private sector organizations, Federally Funded Research and Development Centers (FFRDCs) and Government entities (Government/National laboratories, military educational institutions, etc.)

- This BAA is open to ALL responsible sources
Part I
Application Process

SHERICA TESHOME
Application Process

The BAA Application Process consist of two stages:

- **STAGE 1** – Quad Chart/White Paper Instructions
- **STAGE 2** – Full Proposal Instructions
Stage 1

Quad Chart/White Paper

- Quad Chart/White Paper Preparation
  - Initial submission should not exceed 14 pages
  - Combine all files and forms into a single searchable PDF file
  - Describe the effort in sufficient detail to allow evaluation of the concept’s technical merit and its potential contribution to the BARDA mission

- Format
  - Both Quad Chart and White paper format is explained in BAA solicitation
Stage 1
Quad Chart/White Paper (cont’d)

- Review
  - Technical merit and Program relevance is reviewed by panel
  - An invitation letter to submit full proposal
  - Do not invite letter (full proposal submission not recommended)
  - Technical feedback provided in response letter
  - No debriefing will be provided
Stage 2
Full Proposal

- Full Proposal must be prepared in two separate volumes:
  - **Volume I – Technical Proposal** (detailed instructions located in solicitation)
  - **Volume II – Cost Proposal** (detailed instructions located in solicitation)
Submission Deadlines

This is a rolling solicitation with multiple deadlines for submission:

<table>
<thead>
<tr>
<th>White Paper Submission Deadline Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 January 2016</td>
</tr>
<tr>
<td>30 April 2016</td>
</tr>
<tr>
<td>30 July 2016</td>
</tr>
<tr>
<td>30 October 2016</td>
</tr>
<tr>
<td>30 January 2017</td>
</tr>
<tr>
<td>30 April 2017</td>
</tr>
<tr>
<td>30 July 2017</td>
</tr>
<tr>
<td>30 October 2017</td>
</tr>
<tr>
<td><strong>Final Quad Chart/White Paper Deadline is October 30, 2017</strong></td>
</tr>
<tr>
<td><strong>Full Proposals are due as specified in the invitation letter</strong></td>
</tr>
</tbody>
</table>
Part II – Evaluation Process

George Keane
Technical Evaluation Panel (TEP)

- Panel composed of Government and non-Government subject matter experts
- Three areas examined
  - #1 – Program Relevance
  - #2 – Scientific and Technical Merit
  - #3 – Offeror Capabilities
- Ratings range from Excellent (Best), Good, Fair, Poor (Worst).
Technical Evaluation Report

- Documented results of the TEP
- Report is the basis of the recommendation to the Source Selection Authority (SSA)
Cost Proposal Review

- Basic Cost/Price Information
- Documentation of Proposed Costs
- Allocable, Allowable and Reasonable
- Some areas of special consideration
Salary Rate Limitation

- HHSAR 352.231-70
- Direct Salary cannot exceed Executive Level II
- $183,300 annually (January 2015)
- Applies to subcontractors and consultants as well as prime contractors
ASPR Business Toolkit

- Repository for business templates for submitting a cost proposal
- Documentation of Proposed Costs
- Salary Rate Limitation
- Travel
- Cost Proposal Attachments
- HHS Small Business Subcontracting Plan
- Total Life Cycle Costs

Website: http://www.phe.gov/about/amcg/contracts/Pages/toolkit.aspx
BAA Websites:

- Federal Business Opportunities: [https://www.fbo.gov/](https://www.fbo.gov/)
- Medical Countermeasures: [https://www.medicalcountermeasures.gov](https://www.medicalcountermeasures.gov)
Submission E-mail Addresses:

- SST - SST-BAA@hhs.gov
- CBRN - CBRN-BAA@hhs.gov
- FLU - FLU-BAA@hhs.gov
For Future Contact:

- SST - Wendell Conyers / 202-205-8262 / wendell.conyers@hhs.gov
- CBRN - George Keane / 202-260-5169 / george.keane@hhs.gov
- FLU - Sherica Teshome / 202-205-5919 / sherica.teshome@hhs.gov
Questions?
BARDA INDUSTRY DAY

FY 2015 YEAR IN REVIEW
Cassandra R. Freeman
Division Director, AMCG Division of Acquisition Policy
FY2015 Year in Review

Actions Competed and Awarded
Actions Awarded by Category
Metrics and Efficiencies
## FY15 Competitive Actions

<table>
<thead>
<tr>
<th>Month</th>
<th>Competitive</th>
<th>Non-Competitive</th>
<th>Total Awards</th>
<th>Percentage Competitive</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oct-14</td>
<td>34</td>
<td>2</td>
<td>36</td>
<td>94%</td>
</tr>
<tr>
<td>Nov-14</td>
<td>36</td>
<td>3</td>
<td>39</td>
<td>92%</td>
</tr>
<tr>
<td>Dec-14</td>
<td>66</td>
<td>5</td>
<td>71</td>
<td>93%</td>
</tr>
<tr>
<td>Jan-15</td>
<td>38</td>
<td>6</td>
<td>44</td>
<td>86%</td>
</tr>
<tr>
<td>Feb-15</td>
<td>54</td>
<td>3</td>
<td>57</td>
<td>95%</td>
</tr>
<tr>
<td>Mar-15</td>
<td>71</td>
<td>9</td>
<td>80</td>
<td>89%</td>
</tr>
<tr>
<td>Apr-15</td>
<td>82</td>
<td>6</td>
<td>88</td>
<td>93%</td>
</tr>
<tr>
<td>May-15</td>
<td>58</td>
<td>5</td>
<td>63</td>
<td>92%</td>
</tr>
<tr>
<td>Jun-15</td>
<td>64</td>
<td>9</td>
<td>73</td>
<td>88%</td>
</tr>
<tr>
<td>Jul-15</td>
<td>69</td>
<td>11</td>
<td>80</td>
<td>86%</td>
</tr>
<tr>
<td>Aug-15</td>
<td>69</td>
<td>6</td>
<td>75</td>
<td>92%</td>
</tr>
<tr>
<td>Sep-15</td>
<td>119</td>
<td>24</td>
<td>143</td>
<td>83%</td>
</tr>
<tr>
<td>Total</td>
<td>760</td>
<td>89</td>
<td>849</td>
<td>90%</td>
</tr>
</tbody>
</table>
AMCG Metrics and Efficiencies Acquisition Data

- **Bioshield RFP**: 128 days
- **Ebola**: 60 days
- **I H S (PALT)**: 120 - 180 days
- **VA (PALT)**: 180 - 215 days

*Includes two outliers*